What is the best urine test to determine bone loss, specifically osteoporosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The best urine test to determine bone loss is the N-telopeptide (NTx) test, which measures the level of collagen breakdown products in urine that are released when bone is broken down. This test provides a reliable indicator of the rate of bone resorption, making it valuable for assessing bone loss. To use this test effectively, a second-morning void urine sample is typically collected, and results are normalized to creatinine levels to account for urine concentration differences. The NTx test is particularly useful for monitoring response to osteoporosis treatments, as decreasing levels indicate that therapy is effectively reducing bone breakdown. Other useful urine markers include deoxypyridinoline (DPD) and C-telopeptide (CTx), but NTx is generally preferred for its specificity and reliability, as shown in studies such as 1.

Some key points to consider when using the NTx test include:

  • The test measures the level of collagen breakdown products in urine, which are released when bone is broken down.
  • A second-morning void urine sample is typically collected to minimize variability.
  • Results are normalized to creatinine levels to account for urine concentration differences.
  • The NTx test is useful for monitoring response to osteoporosis treatments, as decreasing levels indicate effective therapy.
  • Other urine markers, such as DPD and CTx, can also be used, but NTx is generally preferred for its specificity and reliability, as supported by studies like 1 and 1.

It's also important to note that while the NTx test is a valuable tool for assessing bone loss, it should be used in conjunction with other assessments, such as bone mineral density scans, for a comprehensive evaluation of bone health, as recommended in guidelines like 1. Additionally, factors such as age, sex, and medical history should be taken into account when interpreting NTx test results, as discussed in studies like 1 and 1.

Overall, the NTx test is a reliable and useful tool for determining bone loss, and its results should be considered in the context of a patient's overall health and medical history, as emphasized in studies like 1, 1, and 1.

From the Research

Urine Tests for Bone Loss

The following urine tests can be used to determine bone loss:

  • Urinary N-telopeptide (U-NTX) 2
  • Urinary cross-linked N-telopeptide of type I collagen (NTX) 3
  • C-telopeptide of type I collagen (CTX-I) 4, 5
  • Free deoxypyridinoline 6

Markers of Bone Turnover

These urine tests measure markers of bone turnover, which include:

  • Bone resorption markers: U-NTX, NTX, CTX-I, free deoxypyridinoline 3, 2, 6
  • Bone formation markers: N-terminal propeptide of type I procollagen (PINP) 4, 5

Clinical Use of Urine Tests

Urine tests can be used to:

  • Assess the response to anabolic and antiresorptive therapies 4, 5
  • Assess compliance to therapy 4, 5
  • Indicate possible secondary causes of osteoporosis 4, 5
  • Monitor anti-osteoporosis therapy 5
  • Identify women who have experienced fast bone loss during the menopause transition 2

Variability and Limitations

Urine tests are subject to sources of variability, including:

  • Feeding (lower resorption) 4, 5
  • Recent fracture (increased levels of all markers) 4, 5
  • Controllable patient-related factors (e.g. blood collection after an overnight fast) 5 Urine tests do not improve prediction of bone loss or fracture within an individual 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Urinary N-telopeptide and Rate of Bone Loss Over the Menopause Transition and Early Postmenopause.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2016

Research

Use of bone turnover markers in postmenopausal osteoporosis.

The lancet. Diabetes & endocrinology, 2017

Research

Bone turnover: Biology and assessment tools.

Best practice & research. Clinical endocrinology & metabolism, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.